AU2001292861A1 - Modified factor VIII - Google Patents

Modified factor VIII

Info

Publication number
AU2001292861A1
AU2001292861A1 AU2001292861A AU9286101A AU2001292861A1 AU 2001292861 A1 AU2001292861 A1 AU 2001292861A1 AU 2001292861 A AU2001292861 A AU 2001292861A AU 9286101 A AU9286101 A AU 9286101A AU 2001292861 A1 AU2001292861 A1 AU 2001292861A1
Authority
AU
Australia
Prior art keywords
factor viii
human
modified
amino acid
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292861A
Other languages
English (en)
Inventor
John S Lollar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of AU2001292861A1 publication Critical patent/AU2001292861A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2001292861A 2000-09-19 2001-09-19 Modified factor VIII Abandoned AU2001292861A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23404700P 2000-09-19 2000-09-19
US60/234,047 2000-09-19
US23646000P 2000-09-29 2000-09-29
US60/236,460 2000-09-29
PCT/US2001/029431 WO2002024723A1 (en) 2000-09-19 2001-09-19 Modified factor viii

Publications (1)

Publication Number Publication Date
AU2001292861A1 true AU2001292861A1 (en) 2002-04-02

Family

ID=26927505

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001292861A Abandoned AU2001292861A1 (en) 2000-09-19 2001-09-19 Modified factor VIII

Country Status (12)

Country Link
US (1) US6770744B2 (hu)
EP (1) EP1319016A4 (hu)
JP (1) JP2004525608A (hu)
KR (1) KR100638184B1 (hu)
CN (1) CN1205221C (hu)
AU (1) AU2001292861A1 (hu)
CA (1) CA2422902A1 (hu)
HU (1) HUP0301179A3 (hu)
MX (1) MXPA03002256A (hu)
PL (1) PL206105B1 (hu)
RU (1) RU2003107100A (hu)
WO (1) WO2002024723A1 (hu)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113970279A (zh) * 2021-10-26 2022-01-25 珠海城市职业技术学院 数字式螺旋测微仪

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
EP1456235A4 (en) * 2001-11-30 2005-08-17 Univ Emory VARIANTS OF DOMAIN C2 OF FACTOR VIII
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
EP1636360A4 (en) 2003-06-03 2006-11-08 Cell Genesys Inc COMPOSITIONS AND METHODS FOR ENHANCED EXPRESSION OF RECOMBINANT POLYPEPTIDES FROM A SINGLE VECTOR USING A PEPTIDE CLEAVAGE SITE
WO2005046583A2 (en) * 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US7855274B2 (en) * 2003-12-03 2010-12-21 University Of Rochester Recombinant factor VIII having increased specific activity
DK1750733T3 (da) * 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
MX350293B (es) 2004-11-12 2017-09-04 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
JP2011502478A (ja) 2007-11-01 2011-01-27 ユニバーシティー オブ ロチェスター 安定性が増大した組換え型第ｖｉｉｉ因子
JP5997443B2 (ja) * 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
CA2780763A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
WO2011088391A2 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
MX347503B (es) 2010-11-05 2017-04-26 Baxalta Inc Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
BR112015013311A2 (pt) 2012-12-07 2017-11-14 Haplomics Inc indução de tolerancia e reparação de mutação do fator 8
EP3001836B1 (en) * 2013-05-10 2019-08-07 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
HUE052074T2 (hu) 2013-06-24 2021-04-28 Xiao Weidong Mutáns VIII-as faktor készítmények és módszerek
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
EP3810647A4 (en) * 2018-04-26 2022-08-17 The University of North Carolina at Chapel Hill METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMOPHILIA
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
EP4314041A1 (en) 2021-03-30 2024-02-07 Aavnergene Inc. Modified plasma clotting factor viii and method of use thereof
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
CN114196677A (zh) * 2021-12-30 2022-03-18 广西医科大学第一附属医院 一种高活性的凝血因子Ⅷ或Ⅷa多肽变体Gly710Ala

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
CA2225189C (en) * 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
WO2001012836A1 (en) * 1999-08-13 2001-02-22 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2 domain in the presence or absence of a bound ligand and methods of use thereof
MXPA02009221A (es) * 2000-03-22 2005-07-25 Octagene Gmbh Produccion de factores de coagulacion sanguineo recombinantes en lineas celular humanas.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113970279A (zh) * 2021-10-26 2022-01-25 珠海城市职业技术学院 数字式螺旋测微仪
CN113970279B (zh) * 2021-10-26 2023-07-07 珠海城市职业技术学院 数字式螺旋测微仪

Also Published As

Publication number Publication date
HUP0301179A2 (hu) 2003-10-28
WO2002024723A9 (en) 2003-04-03
KR100638184B1 (ko) 2006-10-26
US20020182670A1 (en) 2002-12-05
KR20030033074A (ko) 2003-04-26
PL366199A1 (en) 2005-01-24
US6770744B2 (en) 2004-08-03
CN1474830A (zh) 2004-02-11
EP1319016A1 (en) 2003-06-18
PL206105B1 (pl) 2010-07-30
JP2004525608A (ja) 2004-08-26
EP1319016A4 (en) 2006-05-10
CA2422902A1 (en) 2002-03-28
WO2002024723A1 (en) 2002-03-28
RU2003107100A (ru) 2004-08-27
CN1205221C (zh) 2005-06-08
MXPA03002256A (es) 2003-09-10
HUP0301179A3 (en) 2006-11-28

Similar Documents

Publication Publication Date Title
US6770744B2 (en) Modified factor VIII
US5859204A (en) Modified factor VIII
US7122634B2 (en) Modified factor VIII
EP1200105B1 (en) Modified factor viii
US8951515B2 (en) Modified factor VIII
US20050123997A1 (en) Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
AU2001238416A1 (en) Modified factor VIII
EP1062224A1 (en) Modified factor viii
CA2461443C (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
WO2003047507A2 (en) Factor viii c2 domain variants

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application